Amanda Tristram
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Amanda Tristram has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Alison Fiander
School of Medicine, Cardiff University
2 shared publications - Dean Bryant
University of Southampton, Southampton, United Kingdom
2 shared publications - Ned Powell
School of Medicine, Heath Park, Cardiff University, CF64 3RL, UK
2 shared publications - Sam Hibbitts
School of Medicine, Heath Park, Cardiff University, CF64 3RL, UK
2 shared publications Alison Fiander
Is Senior Lecturer in Gynaecological Oncology, Wales College of Medicine, Cardiff University, Heath Park, Cardiff CF14 4XN, UK
1 shared publication- Maribel Almonte
Department of Noncommunicable Diseases, Rehabilitation and Disability, World Health Organization
1 shared publication
Latest Publications
- 1 May 2015
- Published by Elsevier in Journal of Clinical Virology
- Vol. 66, 66-71
Human papillomavirus type 16 L1/L2 DNA methylation shows weak association with cervical disease grade in young women
- 1 May 2015
- Published by Elsevier in Journal of Clinical Virology
- Vol. 66, 66-71
Human papillomavirus type 16 L1/L2 DNA methylation shows weak association with cervical disease grade in young women
- 1 November 2014
- Published by Elsevier in Journal of Clinical Virology
- Vol. 61 (3) , 393-399
Increased methylation of Human Papillomavirus type 16 DNA correlates with viral integration in Vulval Intraepithelial Neoplasia
- 1 November 2014
- Published by Elsevier in Journal of Clinical Virology
- Vol. 61 (3) , 393-399
Increased methylation of Human Papillomavirus type 16 DNA correlates with viral integration in Vulval Intraepithelial Neoplasia
- 25 July 2012
- Published by Taylor & Francis in Future Oncology
- Vol. 8 (7) , 783-786
Should Human Papillomavirus DNA Testing Be Offered in Combination with Cytology or as a Sole Primary Screening Test in Cervical Cancer Prevention?
Evaluation of: Rijkaart DC, Berkhof J, van Kemenade FJ et al. HPV DNA testing in population-based cervical screening (VUSA-Screen study): results and implications. Br. J. Cancer 106(5), 975-981 (2012). Previous studies have shown that the combination of high-risk human papillomavirus (HPV) testing and cytology increases sensitivity for the detection of cervical intraepithelial neoplasia 3, a surrogate end point for the reduction of cervical cancer. This paper addressed three questions regarding the implementation of high-risk HPV testing within a cervical screening program. The main question addressed was whether high-risk HPV testing should be provided as a standalone primary screen or in combination with cytology. Management of HPV-positive women and the optimum age for HPV testing were also examined. Results identified limited benefit from co-testing compared with HPV testing alone and emphasized the importance of repeat testing for HPV-positive women with negative cytology triage at baseline, in all women from 30 years of age onwards.
- 25 July 2012
- Published by Taylor & Francis in Future Oncology
- Vol. 8 (7) , 783-786
Should Human Papillomavirus DNA Testing Be Offered in Combination with Cytology or as a Sole Primary Screening Test in Cervical Cancer Prevention?
Evaluation of: Rijkaart DC, Berkhof J, van Kemenade FJ et al. HPV DNA testing in population-based cervical screening (VUSA-Screen study): results and implications. Br. J. Cancer 106(5), 975-981 (2012). Previous studies have shown that the combination of high-risk human papillomavirus (HPV) testing and cytology increases sensitivity for the detection of cervical intraepithelial neoplasia 3, a surrogate end point for the reduction of cervical cancer. This paper addressed three questions regarding the implementation of high-risk HPV testing within a cervical screening program. The main question addressed was whether high-risk HPV testing should be provided as a standalone primary screen or in combination with cytology. Management of HPV-positive women and the optimum age for HPV testing were also examined. Results identified limited benefit from co-testing compared with HPV testing alone and emphasized the importance of repeat testing for HPV-positive women with negative cytology triage at baseline, in all women from 30 years of age onwards.
- 30 November 2007
- Published by Elsevier in Obstetrics, Gynaecology & Reproductive Medicine
- Vol. 17 (11) , 324-329
Human papillomavirus (including vaccines)
- 30 November 2007
- Published by Elsevier in Obstetrics, Gynaecology & Reproductive Medicine
- Vol. 17 (11) , 324-329
Human papillomavirus (including vaccines)